---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-033949"
form_type: "8-K"
ticker: "BCDA"
cik: "0000925741"
company_name: "BioCardia, Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:51:11.860615+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioCardia announces first patient enrolled at Henry Ford Health in Phase 3 CardiAMP HF II trial

## Summary
- First patient enrolled at Henry Ford Health in Phase 3 CardiAMP HF II trial for ischemic heart failure with reduced ejection fraction.
- Prior CardiAMP HF study showed reduced mortality and major adverse cardiac events in patients with elevated NTproBNP.
- Phase 3 is a 250-patient randomized, placebo-controlled confirmatory study using a three-tier composite primary endpoint.
- Primary endpoint composite: all-cause death, nonfatal MACE, and validated quality of life measure.
- CEO notes ~2 million US and EU patients with NYHA Class II/III symptoms who may benefit.

## SEC filing metadata
- accession: 0001437749-25-033949
- form_type: 8-K
- ticker: BCDA
- cik: 0000925741
- company_name: BioCardia, Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/925741/000143774925033949/0001437749-25-033949-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/925741/000143774925033949/bcda20251110_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-033949
- JSON: https://secwatch.observer/filing/0001437749-25-033949.json
- Plain text: https://secwatch.observer/filing/0001437749-25-033949.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.